SCHEMBL5651523

SCHEMBL5651523

CC(N)(Cc1ccccc1)C1CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.50
TAAR1 Q96RJ0 1/20 0.50
GBA1 P04062 1/20 0.49
HRH1 P35367 4/20 0.46
LMNA P02545 2/20 0.46
CYP2D6 P10635 2/20 0.46
MEN1 O00255 1/20 0.46
SCN1A P35498 1/20 0.46
KMT2A Q03164 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
SLC6A4 P31645 3/20 0.41
SIGMAR1 Q99720 2/20 0.40
SLC18A3 Q16572 1/20 0.40
HTR1A P08908 2/20 0.39
SLC6A3 Q01959 2/20 0.39
GABRA1 P14867 2/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16047194 0.87 SLC6A2 (0.59) SLC6A2TAAR1HRH1LMNACYP2D6
SCHEMBL5649395 0.87 GBA1 (0.46) SLC6A2TAAR1GBA1HRH1LMNA
SCHEMBL9978781 0.84 GBA1 (0.50) SLC6A2TAAR1GBA1HRH1LMNA
SCHEMBL9390741 0.84 SLC6A2 (0.55) SLC6A2TAAR1LMNACYP2D6SLC18A3
SCHEMBL5650003 0.82 GBA1 (0.45) SLC6A2TAAR1GBA1HRH1LMNA
SCHEMBL11861949 0.81 HRH1 (0.53) SLC6A2TAAR1GBA1HRH1LMNA
SCHEMBL5419756 0.81 SLC6A2 (0.52) SLC6A2TAAR1LMNACYP2D6KMT2A
Hydrochloric Acid SCHEMBL11843236 0.80 HRH1 (0.51) SLC6A2TAAR1GBA1HRH1LMNA
SCHEMBL28021430 0.77 HRH1 (0.56) SLC6A2GBA1HRH1LMNACYP2D6
SCHEMBL27714822 0.76 HRH1 (0.44) SLC6A2TAAR1GBA1HRH1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL SLC6A2 4622/4885TAAR1 3829/4885GBA1 451/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL SLC6A2 4264/4885TAAR1 3873/4885GBA1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.